BioMarin Pharmaceutical I... (BMRN)
NASDAQ: BMRN
· Real-Time Price · USD
57.63
-1.35 (-2.29%)
At close: Sep 04, 2025, 10:20 AM
-2.29% (1D)
| Bid | 57.4 |
| Market Cap | 11.07B |
| Revenue (ttm) | 3.06B |
| Net Income (ttm) | 657.24M |
| EPS (ttm) | 3.39 |
| PE Ratio (ttm) | 17 |
| Forward PE | 12.9 |
| Analyst | Buy |
| Ask | 57.52 |
| Volume | 115,207 |
| Avg. Volume (20D) | 2,140,475 |
| Open | 58.91 |
| Previous Close | 58.98 |
| Day's Range | 57.60 - 58.91 |
| 52-Week Range | 52.93 - 90.01 |
| Beta | 0.18 |
About BMRN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol BMRN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for BMRN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
BioMarin Pharmaceutical Inc. is scheduled to release its earnings on
Oct 28, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 weeks ago
+2.69%
BioMarin Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
1 month ago
+3.73%
BioMarin Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 guidance.
1 month ago · seekingalpha.com
BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401BioMarin's revenue growth is strong, with Q2 2025 revenues up 16% year-over-year and full-year guidance raised to $3.125–$3.2 billion. The Inozyme acquisition brings late-stage BMN 401 for ENPP1 defic...
